Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
2077 | 2298 | 35.3 | 77% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CAMPTOTHECIN | Author keyword | 148 | 32% | 16% | 379 |
2 | SN 38 | Author keyword | 108 | 55% | 6% | 137 |
3 | TOPOTECAN | Author keyword | 107 | 33% | 12% | 267 |
4 | CPT 11 | Author keyword | 61 | 36% | 6% | 138 |
5 | 9 NITROCAMPTOTHECIN | Author keyword | 53 | 78% | 2% | 35 |
6 | 9 AMINOCAMPTOTHECIN | Author keyword | 47 | 79% | 1% | 30 |
7 | HOMOCAMPTOTHECIN | Author keyword | 41 | 87% | 1% | 20 |
8 | CAMPTOTHECINS | Author keyword | 40 | 57% | 2% | 47 |
9 | IRINOTECAN | Author keyword | 36 | 13% | 11% | 248 |
10 | TOPOISOMERASE I INHIBITORS | Author keyword | 22 | 49% | 1% | 33 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CAMPTOTHECIN | 148 | 32% | 16% | 379 | Search CAMPTOTHECIN | Search CAMPTOTHECIN |
2 | SN 38 | 108 | 55% | 6% | 137 | Search SN+38 | Search SN+38 |
3 | TOPOTECAN | 107 | 33% | 12% | 267 | Search TOPOTECAN | Search TOPOTECAN |
4 | CPT 11 | 61 | 36% | 6% | 138 | Search CPT+11 | Search CPT+11 |
5 | 9 NITROCAMPTOTHECIN | 53 | 78% | 2% | 35 | Search 9+NITROCAMPTOTHECIN | Search 9+NITROCAMPTOTHECIN |
6 | 9 AMINOCAMPTOTHECIN | 47 | 79% | 1% | 30 | Search 9+AMINOCAMPTOTHECIN | Search 9+AMINOCAMPTOTHECIN |
7 | HOMOCAMPTOTHECIN | 41 | 87% | 1% | 20 | Search HOMOCAMPTOTHECIN | Search HOMOCAMPTOTHECIN |
8 | CAMPTOTHECINS | 40 | 57% | 2% | 47 | Search CAMPTOTHECINS | Search CAMPTOTHECINS |
9 | IRINOTECAN | 36 | 13% | 11% | 248 | Search IRINOTECAN | Search IRINOTECAN |
10 | TOPOISOMERASE I INHIBITORS | 22 | 49% | 1% | 33 | Search TOPOISOMERASE+I+INHIBITORS | Search TOPOISOMERASE+I+INHIBITORS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | NSC 100880 | 188 | 78% | 5% | 124 |
2 | CPT 11 | 166 | 39% | 15% | 337 |
3 | CAMPTOTHECIN | 163 | 26% | 24% | 552 |
4 | DNA TOPOISOMERASE I | 155 | 33% | 17% | 389 |
5 | PLANT ANTITUMOR AGENTS | 145 | 73% | 5% | 110 |
6 | CARBOXYLATE FORMS | 144 | 89% | 3% | 65 |
7 | RING MODIFIED CAMPTOTHECIN | 115 | 83% | 3% | 66 |
8 | SN 38 | 101 | 53% | 6% | 133 |
9 | 20S CAMPTOTHECIN | 99 | 88% | 2% | 46 |
10 | CAMPTOTHECIN DERIVATIVE IRINOTECAN | 99 | 78% | 3% | 66 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Cancer Therapies Utilizing the Camptothecins: A Review of the in Vivo Literature | 2010 | 84 | 285 | 66% |
Perspectives on Biologically Active Camptothecin Derivatives | 2015 | 1 | 115 | 66% |
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) | 2001 | 339 | 132 | 67% |
Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins | 2002 | 271 | 155 | 71% |
Camptothecin: current perspectives | 2004 | 204 | 133 | 59% |
Review Camptothecin: Current Perspectives | 2006 | 98 | 94 | 71% |
Towards new anticancer drugs: a decade of advances in synthesis of camptothecins and related alkaloids | 2003 | 130 | 118 | 64% |
Camptothecins - A review of their chemotherapeutic potential | 2002 | 141 | 144 | 63% |
Clinical applications of the camptothecins | 1998 | 152 | 90 | 79% |
Camptothecin and its analogues: a review on their chemotherapeutic potential | 2005 | 44 | 67 | 75% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | STEHLIN FDN CANC | 13 | 69% | 0.5% | 11 |
2 | DANIEL DEN HOED KLIN | 9 | 26% | 1.3% | 31 |
3 | CAROLINA CANC NANOTECHOL EXCELLENCE | 4 | 75% | 0.1% | 3 |
4 | PEDIAT PHARMACOKINET THER EUT | 3 | 17% | 0.8% | 18 |
5 | GYNECOL ONCOL OUTREACH PROGRAM | 3 | 100% | 0.1% | 3 |
6 | JOINT GREEN CHEM | 3 | 60% | 0.1% | 3 |
7 | PROGRAM MOL THER EUT DRUG DISCOVERY | 2 | 33% | 0.3% | 6 |
8 | MED ON AB EXPT CHEMOTHER Y PHARMACOL | 2 | 67% | 0.1% | 2 |
9 | EXPT CHEMOTHER Y PHARMACOL | 2 | 33% | 0.2% | 4 |
10 | ROTTERDAM CANC | 2 | 14% | 0.4% | 10 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000258602 | NOTHAPODYTES FOETIDA//CAMPTOTHECA ACUMINATA//OPHIORRHIZA PUMILA |
2 | 0.0000123116 | TOPOISOMERASE II//ICRF 193//DNA TOPOISOMERASE II |
3 | 0.0000071801 | CARBOXYLESTERASE//DRUG METAB BIOPHARMACEUT//CARBOXYLESTERASES |
4 | 0.0000069034 | OXALIPLATIN//CAPECITABINE//IRINOTECAN |
5 | 0.0000056244 | PLATINUM RESISTANT//RECURRENT OVARIAN CANCER//PEGYLATED LIPOSOMAL DOXORUBICIN |
6 | 0.0000052674 | ABCG2//BCRP//BREAST CANCER RESISTANCE PROTEIN |
7 | 0.0000044036 | HPMA COPOLYMERS//HPMA COPOLYMER//POLYMER THER EUT |
8 | 0.0000040739 | LIPOSOMAL CISPLATIN//LIPOPLATIN//SPI 077 |
9 | 0.0000039405 | VINORELBINE//GEMCITABINE//ADVANCED NON SMALL CELL LUNG CANCER |
10 | 0.0000038972 | BENZOCPHENANTHRIDINE//INDENOISOQUINOLINE//3 ARYLISOQUINOLINE |